Ezallor Sprinkle

— THERAPEUTIC DISORDERS TREATED —
  • Hyperlipoproteinemias

Ezallor Sprinkle Generic Name & Formulations

General Description

Rosuvastatin (as calcium) 5mg, 10mg, 20mg, 40mg; caps.

Pharmacological Class

HMG-CoA reductase inhibitor.

How Supplied

Caps 5mg, 10mg, 20mg, 40mg—30, 90

Generic Availability

NO

Ezallor Sprinkle Indications

Indications

Adjunct to diet in hypertriglyceridemia. Adjunct to diet in primary dysbetalipoproteinemia (Type III hyperlipoproteinemia). Adjunct to other lipid-lowering treatments (or if these treatments are unavailable), in homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB.

Limitations of Use

Not studied in Fredrickson Type I and V dyslipidemias.

Ezallor Sprinkle Dosage and Administration

Adult

Swallow whole. If unable to swallow caps, can open and sprinkle contents onto applesauce; consume immediately. May be given via NG tube. Take once daily. Dose range 5–40mg. HoFH: initially 20mg. All others: usual starting dose 10–20mg. Use max 40mg dose only if 20mg is insufficient. Asian patients: consider 5mg initially (see full labeling). Concomitant cyclosporine, darolutamide: max 5mg. Concomitant regorafenib: max 10mg. Concomitant atazanavir/ritonavir, lopinavir/ritonavir, simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir: initially 5mg; max 10mg. Concomitant gemfibrozil (if unavoidable): initially 5mg; max 10mg. Severe renal impairment (CrCl <30mL/min) not on hemodialysis: initially 5mg; max 10mg.

Children

<18yrs: not established.

Ezallor Sprinkle Contraindications

Contraindications

Active liver disease. Unexplained persistent elevated serum transaminases. Pregnancy. Nursing mothers.

Ezallor Sprinkle Boxed Warnings

Not Applicable

Ezallor Sprinkle Warnings/Precautions

Warnings/Precautions

Discontinue if myopathy or elevated CK levels occur; suspend if a predisposition to development of renal failure secondary to rhabdomyolysis develops. Immune-mediated necrotizing myopathy; monitor. Monitor liver function before starting therapy and as clinically indicated. Interrupt therapy if serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs; do not restart if alternate etiology not found. History of liver disease or heavy alcohol ingestion. Severe renal impairment. Hypothyroidism (if inadequately treated). Asian patients. Elderly (≥65yrs). Advise females of reproductive potential to use effective contraception during treatment.

Ezallor Sprinkle Pharmacokinetics

See Literature

Ezallor Sprinkle Interactions

Interactions

See Adults. Avoid gemfibrozil. Increased risk of myopathy with niacin (≥1g/day), fenofibrates, cyclosporine, darolutamide, regorafenib, atazanavir/ritonavir, lopinavir/ritonavir, simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, colchicine; use caution. Concomitant with sofosbuvir/velpatasvir/voxilaprevir, ledipasvir/sofosbuvir: not recommended. Monitor INR with anticoagulants. Caution with drugs that decrease levels or activity of steroid hormones (eg, ketoconazole, spironolactone, cimetidine). Separate dosing of antacids (give ≥2hrs after rosuvastatin).

Ezallor Sprinkle Adverse Reactions

Adverse Reactions

Headache, myalgia, abdominal pain, asthenia, nausea; myopathy, rhabdomyolysis with renal dysfunction, elevated liver enzymes, proteinuria and hematuria (consider dose reduction if persistent), increased HbA1c and fasting serum glucose, rare: cognitive impairment, hepatic failure.

Ezallor Sprinkle Clinical Trials

See Literature

Ezallor Sprinkle Note

Not Applicable

Ezallor Sprinkle Patient Counseling

See Literature